Pacgen Life Science Corporation announced that it has entered agreements with DermaMed Pharmaceutical Inc. and Deserving Health International Corp, granting Pacgen exclusive global marketing, sales, and distribution rights to their innovative personal care products. The agreements provide Pacgen with access to over 50 natural therapeutic and personal care products under the brand names of DermaMed, DermaSoleil and Deserving Health, as well as DermaMed's current distribution network and warehousing facilities. Global demand for natural and organic consumer healthcare products is growing rapidly and its market potential is expected to exceed $20 billion by 2025 at an compound annual growth rate (CAGR) of over 9%, according to multiple sources. These new commercial rights allow Pacgen to expand its personal care product portfolio, which currently includes oral health and feminine hygiene products containing P113, an antimicrobial peptide derived from a naturally occurring histatin protein. These P113+ products are currently marketed under the brand name of 'Oh-Care' in Taiwan and Southern China. Pacgen intends on leveraging its existing distribution networks in these and other Asian regions to expand the DermaMed, DermaSoleil and Deserving Health markets.